📊 BLRX Key Takeaways
Is BioLineRx Ltd. (BLRX) a Good Investment?
Insufficient financial data available to conduct a meaningful fundamental analysis. All key financial metrics including revenue, profitability, assets, liabilities, and cash flow are not provided or not available in the SEC EDGAR data. Without access to actual financial statements and key performance indicators, a reliable investment assessment cannot be made.
BioLineRx's fundamentals remain weak despite meaningful cost cuts and a stronger mid-2025 liquidity position. The core issue is revenue quality: six-month 2025 revenue fell to about $0.6 million from $12.2 million a year earlier, while reported net income was driven by non-operating items rather than sustainable operating profitability. With recurring operating losses, debt obligations, and a stated going-concern warning in its 2024 annual filing, the business still depends heavily on external milestones, royalties, and capital access.
Why Buy BioLineRx Ltd. Stock? BLRX Key Strengths
- No strengths identified
- Operating loss improved materially to about $4.7 million in H1 2025 from $10.6 million in H1 2024 as commercial and overhead costs were reduced
- Cash, cash equivalents, and short-term deposits increased to about $28.2 million as of June 30, 2025, improving near-term liquidity
- Balance sheet pressure eased versus year-end 2024, with total liabilities declining and current assets covering current liabilities by roughly 2x
BLRX Stock Risks: BioLineRx Ltd. Investment Risks
- Complete absence of financial data prevents fundamental analysis
- Unable to assess profitability, liquidity, or solvency metrics
- No visibility into operational performance or cash generation capability
- Pharmaceutical sector inherently carries significant R&D and regulatory risks that cannot be evaluated without financial information
- Revenue deteriorated sharply, with H1 2025 total revenue dropping about 95% year over year, showing weak underlying commercial traction
- Positive H1 2025 net income came from non-operating gains, not durable core earnings, so profitability quality is low
- The company disclosed substantial doubt about its ability to continue as a going concern and may need additional capital while still carrying loan obligations
Key Metrics to Watch
- Revenue and gross profit once financial statements become available
- Cash position and burn rate critical for pre-revenue or early-stage biotech companies
- Operating cash flow and runway to determine financial sustainability
- Clinical trial progress and pipeline advancement for drug candidates
- Balance sheet strength and access to capital for ongoing R&D funding
- Quarterly royalty and milestone revenue from APHEXDA and partner agreements
- Operating cash burn relative to cash plus short-term deposits and scheduled debt repayments
BioLineRx Ltd. (BLRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BLRX Profit Margin, ROE & Profitability Analysis
BLRX vs Healthcare Sector: How BioLineRx Ltd. Compares
How BioLineRx Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioLineRx Ltd. Stock Overvalued? BLRX Valuation Analysis 2026
Based on fundamental analysis, BioLineRx Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioLineRx Ltd. Balance Sheet: BLRX Debt, Cash & Liquidity
BLRX Revenue Growth, EPS Growth & YoY Performance
BLRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioLineRx Ltd. (CIK: 0001498403)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BLRX
What is the AI rating for BLRX?
BioLineRx Ltd. (BLRX) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 52% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BLRX's key strengths?
Claude: . ChatGPT: Operating loss improved materially to about $4.7 million in H1 2025 from $10.6 million in H1 2024 as commercial and overhead costs were reduced. Cash, cash equivalents, and short-term deposits increased to about $28.2 million as of June 30, 2025, improving near-term liquidity.
What are the risks of investing in BLRX?
Claude: Complete absence of financial data prevents fundamental analysis. Unable to assess profitability, liquidity, or solvency metrics. ChatGPT: Revenue deteriorated sharply, with H1 2025 total revenue dropping about 95% year over year, showing weak underlying commercial traction. Positive H1 2025 net income came from non-operating gains, not durable core earnings, so profitability quality is low.
What is BLRX's revenue and growth?
BioLineRx Ltd. reported revenue of N/A.
Does BLRX pay dividends?
BioLineRx Ltd. does not currently pay dividends.
Where can I find BLRX SEC filings?
Official SEC filings for BioLineRx Ltd. (CIK: 0001498403) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BLRX's EPS?
BioLineRx Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BLRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BioLineRx Ltd. has a SELL rating with 52% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BLRX stock overvalued or undervalued?
Valuation metrics for BLRX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BLRX stock in 2026?
Our dual AI analysis gives BioLineRx Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BLRX's free cash flow?
BioLineRx Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does BLRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).